Impact of Vitamin D Deficiency on the Efficacy of Atorvastatin in Iraqi Patients with Dyslipidemia
DOI:
https://doi.org/10.31351/vol35iss3pp38-45Keywords:
Atherogenic index, Atorvastatin, Cholesterol, Dyslipidemia, Vitamin D3Abstract
Dyslipidemia is an abnormal elevation of lipid levels in the blood, which may involve cholesterol and triglycerides. The response of dyslipidemia to statin therapy is diverse, ranging from 5-70% and this may be related to vitamin D3 deficiency. A study aims to assess the effect of vitamin D3 deficiency on the therapeutic response to atorvastatin. The cohort study involved 243 dyslipidemic patients who received different doses of atorvastatin according to the 2018 American Heart Association/American College of Cardiology cholesterol guidelines. The serum lipid profile level, vitamin D3, and atherogenic index were measured. The serum level of Total cholesterol and low-density lipoprotein-cholesterol, and atherogenic index were significantly reduced, and the serum level of high-density lipoprotein-cholesterol was elevated considerably in the responded patients compared to the non-responded patients at P <0.05. The serum level of vitamin D3 was significantly low in the non-responded patients compared to respond patients at P <0.05. There was a significant association between vitamin D3 deficiency (95% CI 0.759 – 0.849) and a decrease in the efficacy of atorvastatin at P <0.05. In conclusion, Vitamin D3 deficiency significantly reduces the effectiveness of atorvastatin (ATO) in Iraqi patients with dyslipidemia.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Natesan V, Kim S-J. Lipid metabolism, disorders and therapeutic drugs–review. Biomolecules & therapeutics. 2021;29(6):596.
Banach M, Surma S, Toth PP. 2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? Archives of Medical Science: AMS. 2023;19(6):1602.
Chen L, Chen S, Bai X, Su M, He L, Li G, et al. Low-density lipoprotein cholesterol, cardiovascular disease risk, and mortality in China. JAMA Network Open. 2024;7(7):e2422558-e.
Dibaba DT. Effect of vitamin D supplementation on serum lipid profiles: a systematic review and meta-analysis. Nutrition reviews. 2019;77(12):890-902.
Srisawasdi P, Rodcharoen P, Vanavanan S, Chittamma A, Sukasem C, Na nakorn C, Dejthevaporn C, Kroll MH. Association of CETP gene variants with atherogenic dyslipidemia among thai patients treated with statin. Pharmacogenomics and Personalized Medicine. 2021; 6:1-3..
Yow H-Y, Hamzah S, Rahim NA, Suppiah V. Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review. Asian Biomedicine: Research, Reviews and News. 2023;17(3):95.
Hadi SM, Ouda MH, Mohammed Alboaklah HK. Association of Vitamin D 3 Deficiency and Osteoporosis. Review. Karbala Journal of Pharmaceutical Sciences. 2022;1(20).
AlQuaiz AM, Kazi A, Youssef RM, Alshehri N, Alduraywish SA. Association between standardized vitamin 25 (OH) D and dyslipidemia: a community-based study in Riyadh, Saudi Arabia. Environmental health and preventive medicine. 2020;25(1):4.
Mohd Ghozali N, Giribabu N, Salleh N. Mechanisms linking vitamin D deficiency to impaired metabolism: An overview. International Journal of Endocrinology. 2022;2022(1):6453882.
Li S, He Y, Lin S, Hao L, Ye Y, Lv L, et al. Increase of circulating cholesterol in vitamin D deficiency is linked to reduced vitamin D receptor activity via the Insig‐2/SREBP‐2 pathway. Molecular nutrition & food research. 2016;60(4):798-809.
Zittermann A, F Gummert J, Borgermann J. The role of vitamin D in dyslipidemia and cardiovascular disease. Current pharmaceutical design. 2011;17(9):933-42.
Warren T, McAllister R, Morgan A, Rai TS, McGilligan V, Ennis M, et al. The interdependency and co-regulation of the vitamin D and cholesterol metabolism. Cells. 2021;10(8):2007.
Ayçiçek GŞ, Aydoğan Bİ, Şahin M, Emral R, Erdoğan MF, Güllü S, et al. The impact of vitamin D deficiency on clinical, biochemical and metabolic parameters in primary hyperparathyroidism. Endocrinología, Diabetes y Nutrición (English ed). 2023;70(1):56-62.
Grundy SM. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082.
Limenh LW, Tessema TA, Simegn W, Ayenew W, Bayleyegn ZW, Sendekie AK, et al. Patients’ preference for pharmaceutical dosage forms: does it affect medication adherence? A cross-sectional study in community pharmacies. Patient preference and adherence. 2024:753-66.
Sarzani R, Giulietti F, Allevi M, Sarnari S, Alessandroni R, Di Pentima C, et al. Statin-Associated Muscle Symptoms: Clinical Index in a hypertensive population candidated to lipid-lowering therapy but not taking statins: Selected Abstract–Spring Meeting 2023. European Atherosclerosis Journal. 2023;2(1):19-.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.
Maki KC, Grant JK, Orringer CE. LDL-C estimation: the perils of living with imperfection. American College of Cardiology Foundation Washington DC; 2022. p. 542-4.
Saadon HB. Vitamin D and type 2 diabetes mellitus: mechanisms, clinical evidence, and future perspectives. Bulletin of the National Research Centre. 2025;49(1):82.
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta‐analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics. 2010;35(2):139-51.
Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2015; 2015(3): CD008226.
Kee PS, Chin PKL, Kennedy MA, Maggo SD. Pharmacogenetics of statin-induced myotoxicity. Frontiers in genetics. 2020;11:575678.
Lioy B, Webb RJ, Amirabdollahian F, editors. The association between the atherogenic index of plasma and cardiometabolic risk factors: a review. Healthcare; 2023: MDPI.
Mahmoodi MR, Najafipour H. Associations between serum vitamin D3, atherogenic indices of plasma and cardiometabolic biomarkers among patients with diabetes in the KERCADR study. BMC Endocrine Disorders. 2022;22(1):126.
Guan C, Fu S, Zhen D, Li X, Niu J, Cheng J, et al. Correlation of serum vitamin D with lipid profiles in middle-aged and elderly Chinese individuals. Asia Pacific Journal of Clinical Nutrition. 2020;29(4):839-45.
Hileman CO, Tangpricha V, Sattar A, McComsey GA. Baseline vitamin D deficiency decreases the effectiveness of statins in HIV-infected adults on antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;74(5):539-47.
Qin XF, Zhao LS, Chen WR, Yin DW, Wang H. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: a randomized placebo-controlled trial. Clinical Nutrition. 2015;34(2):201-6.
Zou L, Porter TD. Rapid suppression of 7-dehydrocholesterol reductase activity in keratinocytes by vitamin D. The Journal of steroid biochemistry and molecular biology. 2015;148:64-71.
Nardin M, Verdoia M, Nardin S, Cao D, Chiarito M, Kedhi E, et al. Vitamin D and cardiovascular diseases: from physiology to pathophysiology and outcomes. Biomedicines. 2024;12(4):768.
Downloads
Published
License
Copyright (c) 2026 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
